Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGMT | P16455 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.31 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26016262 | 1.00 | MGMT (0.35) | MGMTABCG2BLMPMP22HSD17B10 | |
| SCHEMBL13658532 | 1.00 | MGMT (0.35) | MGMTABCG2BLMPMP22HSD17B10 | |
| SCHEMBL26692655 | 1.00 | MGMT (0.35) | MGMTABCG2BLMPMP22HSD17B10 | |
| SCHEMBL20383110 | 1.00 | MGMT (0.35) | MGMTABCG2BLMPMP22HSD17B10 | |
| SCHEMBL14713433 | 1.00 | MGMT (0.35) | MGMTABCG2BLMPMP22HSD17B10 | |
| SCHEMBL19581482 | 1.00 | MGMT (0.35) | MGMTABCG2BLMPMP22HSD17B10 | |
| SCHEMBL31395671 | 1.00 | MGMT (0.35) | MGMTABCG2BLMPMP22HSD17B10 | |
| SCHEMBL29649445 | 1.00 | MGMT (0.35) | MGMTABCG2BLMPMP22HSD17B10 | |
| SCHEMBL22444946 | 1.00 | MGMT (0.35) | MGMTABCG2BLMPMP22HSD17B10 | |
| SCHEMBL15669474 | 1.00 | MGMT (0.35) | MGMTABCG2BLMPMP22HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | AVILAR THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| WO-2026087903-A1 | ANTIBODIES CONJUGATED TO CYCLOPROPYLBENZOINDOLE DIMER DRUG MOIETIES, AND METHODS OF USE AND TREATMENT | Iksuda Therapeutics Limited (GB) | 2026-04-30 | — | — | WO | disclosed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| EP-4595978-A1 | ANTI-CD33 ANTIBODY AND ANTI-CD33 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | SystImmune, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4525926-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4525925-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| CN-114929729-B | Nucleic acid complex and pharmaceutical composition containing the same | 卫材R&D管理有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240335555-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD. | 2024-10-10 | — | — | US | disclosed |
| CN-114728077-A | MCL-1 inhibitor antibody-drug conjugates and methods of use | 诺华股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114728076-A | MCL-1 inhibitor antibody-drug conjugates and methods of use | 诺华股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-11370801-B2 | Pyrrolobenzodiazepine conjugates | MEDIMMUNE LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| WO-2022133281-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022115477-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115451-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| EP-3972649-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| WO-2020236817-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020236825-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | MGMT 901/4885ABCG2 247/4885BLM 2645/4885 |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MET, BCL3, BCL9 | MGMT 21/4885ABCG2 357/4885BLM 2046/4885 |
| US-11370801-B2 | Pyrrolobenzodiazepine conjugates | NR0B2, HRH3, NR0B1 | MGMT 2372/4885ABCG2 377/4885BLM 3517/4885 |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | IGF2R, M6PR, MSR1 | MGMT 3960/4885ABCG2 1557/4885BLM 3668/4885 |
| US-20240335555-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | HAVCR2, ACE2, EPCAM | MGMT 1430/4885ABCG2 4879/4885BLM 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.